Skip to content

Author

Haruhito Azuma

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Multiplex Immunofluorescence-defined CXCL13-associated TLS-like Niches Predict Outcome in Bladder Cancer.

PURPOSE Spatially organized tertiary lymphoid structure (TLS)-like niches may provide prognostic and therapeutic information beyond individual immune mediators such as CXCL13 in bladder cancer (BC). We evaluated the clinical and translational significance of multiplex immunofluorescence-defined TLS-like structures (mTL...

R. Maenosono, Kazuki Nishimura, T. Tsujino et al. · 0 citations
Open access Oct 2026

Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma

Enfortumab vedotin (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma. Further characterization of clinical heterogeneity and toxicity may complement existing Japanese real‐world data.

T. Tsujino, K. Tamura, R. Taoka et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.